Navigation Links
Receptos Files Registration Statement for Proposed Initial Public Offering
Date:4/4/2013

SAN DIEGO, April 4, 2013 /PRNewswire/ -- Receptos, Inc., a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of shares of its common stock.  All shares of the common stock to be sold in the offering will be offered by Receptos.  The number of shares to be offered and the price range for the offering have not yet been determined.

Credit Suisse Securities (USA) LLC, Leerink Swann LLC and BMO Capital Markets are acting as joint book-running managers for the offering.  Wedbush PacGrow Life Sciences is acting as a co-manager.  The offering will be made only by means of a prospectus.  When available, copies of the preliminary prospectus relating to and describing the terms of the offering may be obtained from Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, One Madison Avenue, New York, NY 10010, Telephone: (800) 221-1037, Email: newyork.prospectus@credit-suisse.com; from Leerink Swann LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, Telephone: (800) 808-7525, Email: syndicate@leerink.com; or from BMO Capital Markets, Attention: Equity Syndicate Department, 3 Times Square, New York, NY 10036, Telephone: (800) 414-3627, Email: bmoprospectus@bmo.com.

A registration statement relating to these securities has been filed with the SEC, but has not yet become effective.  These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective.  This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Receptos

Receptos is a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases. The company's lead program, RPC1063, is a sphingosine 1-phosphate 1 receptor  (S1P1R) small molecule modulator candidate for immune indications, including relapsing multiple sclerosis (RMS) and inflammatory bowel disease (IBD). The company is also developing RPC4046, an anti-interleukin-13 (IL-13) antibody for an allergic/immune-mediated Orphan Disease, eosinophilic esophagitis (EoE). Receptos has established expertise in high resolution protein crystal structure determination, biology and drug discovery for G-protein-coupled receptors (GPCRs).

Media and Investor Contact: 
Graham K. Cooper
Chief Financial Officer, Receptos
(858) 652-5708
gcooper@receptos.com

 

 

 

 


'/>"/>
SOURCE Receptos, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Receptos to Deliver Scientific Presentation at Digestive Disease Week 2012 about the Therapeutic Role of RPC1063 in Inflammatory Bowel Disease
2. Receptos to Present at the 2012 Wedbush PacGrow Life Sciences Management Access Conference
3. Graham Cooper Appointed Chief Financial Officer of Receptos
4. Receptos Determines Novel GPCR Structure, Achieves Key Milestone in Collaboration with Ono Pharmaceuticals
5. Receptos Licenses Anti-Interleukin-13 Antibody from AbbVie for Phase 2 Development in Orphan Disease
6. Ameritox Files Amended Complaint Against Millennium Laboratories For Injunctive Relief, Declaratory Relief and Damages
7. WuXi PharmaTech Files 2011 Annual Report on Form 20-F
8. Mindray Files Annual Report on Form 20-F with the U.S. Securities and Exchange Commission
9. ShangPharma Corporation Files 2011 Annual Report on Form 20-F
10. Sunpeaks Ventures Files Defamation Lawsuit
11. Everett Laboratories, Inc. Files Patent Infringement Lawsuit Against Competitor Trigen Laboratories, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/2/2017)... MEMPHIS, Tenn. and BENTON, Ky. , Aug. 2, 2017 /PRNewswire/ ... new member to its environmental services (ES) team to proactively reduce the risk of hospital-acquired ... is a UV disinfection robot that uses UVC light energy to kill deadly pathogens such ... ... Tru-D ...
(Date:7/31/2017)... 31, 2017 Three Tru-D SmartUVC robots have arrived ... Korea . Tru-D, short for "Total Room Ultraviolet Disinfection," is a ... an environmental services (ES) professional cleans the area with traditional cleaning protocols. ... Tru-D fights germs ... "Although the BAACH has a very ...
(Date:7/27/2017)... Services, Inc. (NYSE: WST ) today announced ... financial guidance for the full-year 2017. ... Reported net sales of $397.6 million, a record high, ... constant currency (organic) grew by 3.9%. ... in the prior-year quarter. Second-quarter 2017 adjusted diluted EPS ...
Breaking Medicine Technology:
(Date:8/23/2017)... Jose, California (PRWEB) , ... August 23, 2017 , ... ... San Jose, California, office at 1530 The Alameda, Suite 115. The office is located ... has changed, the contact information remains the same. Clients can still call the office ...
(Date:8/23/2017)... ... 2017 , ... Earlier this month, the Workgroup for Electronic Data Interchange ... create efficiencies in healthcare information exchange and a trusted advisor to the U.S. Department ... featured keynote addresses by Donald W. Rucker, MD, head of the Office of the ...
(Date:8/23/2017)... Ogden, Utah (PRWEB) , ... August 23, 2017 , ... ... 2013. , Give Back Day is a time Nightingale College dedicates to serving ... with organizations that thrive on donations and volunteers or those that need a little ...
(Date:8/23/2017)... Elkhart, Indiana (PRWEB) , ... August 23, 2017 ... ... Whitney Boling, MD , has returned home to Indiana, and is now ... Boling is a board-eligible ophthalmologist that specializes in the diagnosis and treatment of ...
(Date:8/23/2017)... ... August 23, 2017 , ... TSC ... Awards® - for Risk Management Solution Innovations and Security Solution for Government Innovations. ... released in 2017 and its DHS SAFETY Act-designated enterprise security assessment approach. , ...
Breaking Medicine News(10 mins):